Guillermina Flores-Ferro

Ocoyoacac, MEX 52750, Mexico

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 72 publications

Enhancing Cytosolic Internalization of [177Lu]Lu-iPSMA in Prostate Cancer Cells: The Effect of Conjugating a GRP78 Inhibitor to the Radiotherapeutic Molecule.

Enhancing Cytosolic Internalization of [177Lu]Lu-iPSMA in Prostate Cancer Cells: The Effect of Conjugating a GRP78 Inhibitor to the Radiotherapeutic Molecule.

Journal: International journal of molecular sciences

Published: November 04, 2025

Effects of Targeted Radionuclide Therapy on Cancer Cells Beyond the Ablative Radiation Dose.

Effects of Targeted Radionuclide Therapy on Cancer Cells Beyond the Ablative Radiation Dose.

Journal: International journal of molecular sciences

Published: June 11, 2025

Synthesis and Evaluation of [18F]AlF-NOTA-iPD-L1 as a Potential Theranostic Pair for [177Lu]Lu-DOTA-iPD-L1.

Synthesis and Evaluation of [18F]AlF-NOTA-iPD-L1 as a Potential Theranostic Pair for [177Lu]Lu-DOTA-iPD-L1.

Journal: Pharmaceutics

Published: May 30, 2025

Analysis of Inflammatory and Angiogenic Activities in Patients with Abdominal Aortic Aneurysms with the Radiotracers 99mTc-HYNIC-CCR2-L and 99mTc-RGD with Single-Photon Emission Computed Tomography.

Analysis of Inflammatory and Angiogenic Activities in Patients with Abdominal Aortic Aneurysms with the Radiotracers 99mTc-HYNIC-CCR2-L and 99mTc-RGD with Single-Photon Emission Computed Tomography.

Journal: Annals of vascular surgery

Published: May 09, 2025

Radiobiological effect of alpha particles. The scientific basis of targeted alpha-particle therapy.

Radiobiological effect of alpha particles. The scientific basis of targeted alpha-particle therapy.

Journal: Nuclear medicine and biology

Published: December 02, 2024

Lutetium-177 labeled iPD-L1 as a novel immunomodulator for cancer-targeted radiotherapy.

Lutetium-177 labeled iPD-L1 as a novel immunomodulator for cancer-targeted radiotherapy.

Journal: EJNMMI radiopharmacy and chemistry

Published: December 02, 2024

Theranostic Potential of the iPSMA-Bombesin Radioligand in Patients with Metastatic Prostate Cancer: A Pilot Study.

Theranostic Potential of the iPSMA-Bombesin Radioligand in Patients with Metastatic Prostate Cancer: A Pilot Study.

Journal: Pharmaceutics

Published: September 21, 2024

Analysis of small abdominal aortic aneurysms with the radiotracer technetium-99m- 6-hydrazinylnicotinoyl-C-C-chemokine receptor-2 ligand (99mTc-HYNIC-CCR2-L) with single-photon emission computed tomography.

Analysis of small abdominal aortic aneurysms with the radiotracer technetium-99m- 6-hydrazinylnicotinoyl-C-C-chemokine receptor-2 ligand (99mTc-HYNIC-CCR2-L) with single-photon emission computed tomography.

Journal: Polish journal of radiology

Published: August 15, 2024

Comparison of the dosimetry and cell survival effect of 177Lu and 161Tb somatostatin analog radiopharmaceuticals in cancer cell clusters and micrometastases.

Comparison of the dosimetry and cell survival effect of 177Lu and 161Tb somatostatin analog radiopharmaceuticals in cancer cell clusters and micrometastases.

Journal: EJNMMI physics

Published: July 10, 2024

68Ga-DOTA-D-Alanine-BoroPro Radiotracer for Imaging of the Fibroblast Activation Protein in Malignant and Non-Malignant Diseases.

68Ga-DOTA-D-Alanine-BoroPro Radiotracer for Imaging of the Fibroblast Activation Protein in Malignant and Non-Malignant Diseases.

Journal: Pharmaceutics

Published: January 09, 2024

Molecularly Targeted Lanthanide Nanoparticles for Cancer Theranostic Applications.

Molecularly Targeted Lanthanide Nanoparticles for Cancer Theranostic Applications.

Journal: Nanomaterials (Basel, Switzerland)

Published: December 15, 2023

Development and Characterization of 99mTc-scFvD2B as a Potential Radiopharmaceutical for SPECT Imaging of Prostate Cancer.

Development and Characterization of 99mTc-scFvD2B as a Potential Radiopharmaceutical for SPECT Imaging of Prostate Cancer.

Journal: International journal of molecular sciences

Published: November 27, 2023

Showing 1-12 of 72

Last Updated: 09/26/2026